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Abstract 
Background  
Kidney transplantation (KT) may restore fertility in CKD. The reasons why materno-
foetal outcomes are still inferior to the overall population are only partially known. 
Comparison with the CKD population may offer some useful insights for 
management and counselling.   
Aim of this study was to analyse the outcomes of pregnancy after KT, compared with 
a large population of non-transplanted CKD patients and with low-risk control 
pregnancies, observed in Italy the new millennium.  
Methods 
We selected 121 live-born singletons after KT (Italian study group of kidney in 
pregnancy, national coverage about 75%), 610 live-born singletons in CKD and 1418 
low-risk controls recruited in 2 large Italian Units, in the same period (2000-2014). 
The following outcomes were considered:  maternal and foetal death; malformations; 
preterm delivery; small for gestational age baby (SGA); need for the neonatal 
intensive care unit (NICU); doubling of serum creatinine or increase in CKD stage. 
Data were analysed according to kidney diseases, renal function (staging according to 
CKD-EPI), hypertension, maternal age, partity, ethnicity. 
Results.   
Materno-foetal outcomes are less favourable in CKD and KT as compared with the 
low-risk population. CKD stage and hypertension are important determinants of 
results. KT patients with e-GFR >90 have worse outcomes compared with CKD stage 
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1 patients; the differences level off when only CKD patients affected by 
glomerulonephritis or systemic diseases ("progressive CKD") are compared with KT. 
In the multivariate analysis, risk for preterm and early-preterm delivery was linked to 
CKD stage (2-5 versus 1: RR 3.42 and 3.78) and hypertension (RR 3.68 and 3.16) 
while no difference was associated with being a KT or a CKD patient.  
Conclusions. 
The materno-foetal outcomes in patients with kidney transplantation are comparable 
with those of nontransplanted CKD patients with similar levels of kidney function 
impairment and progressive and/or immunologic kidney disease. 
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Introduction 
Among the many advantages of kidney transplantation over dialysis, pregnancy is of 
particular relevance for young patients, and successful delivery after transplantation is 
considered by patients and physicians as one of the main achievements of this therapy 
(1-4).  
According to a recent in-depth systematic review that includes over 4,700 
transplanted patients, post-KT pregnancy is feasible, but complication rates are still 
relatively high as compared to the general population in the USA (5). The reasons for 
this are not fully understood: the presence of impaired renal function, hypertension 
and proteinuria were identified as important determinants of the outcomes (6-10), as 
were interval between transplantation and pregnancy (5, 11-12), maternal age (4-5) 
and immunosuppressive drugs (1, 13-15). 
While it may be intuitive that patients with a transplanted kidney and impaired renal 
function are at higher risk for adverse pregnancy-related outcomes, as is extensively 
described in nontransplanted patients with CKD, the degree of risk has never been 
fully assessed (16-20). This is also due to the high heterogeneity of the study 
populations and of the controls, as well as to the lack of common terminology and of 
reliable measurements of kidney function in both physiological pregnancies and in 
pregnancies complicated by preeclampsia or kidney disease (21-27).  
One of the effects of CKD reclassification in the new millennium was to focus 
attention on various situations, including pregnancy, in the early stages of the disease 
(16-17, 28-32). Changes in the definition of CKD went hand in hand with the progress 
being made in Maternal-Fetal medicine and neonatal care, which included anticipated 
the timing of “viable” delivery, while the new therapies allowed the indications for 
kidney transplantation to be further broadened (33-37).  
The new millennium is also the era of patient empowerment, making way for 
counseling in delicate situations, such as pregnancy in CKD or after kidney 
transplantation (38-41).  
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The aim of this collaborative study was to analyze the risks for adverse pregnancy-
related outcomes in the new millennium in a nation-wide Italian cohort of kidney 
transplant patients and to compare the data to a large multi-center cohort of CKD 
patients and low-risk pregnancies using the data from the 2014 update of the Torino-
Cagliari Observational Study on CKD and pregnancy (TOCOS study) and applying 
the stratification criteria previously established in CKD (42). The results of such a 
comparison may cast light on the weight of immunosuppressive therapies and of renal 
function derangements in determining pregnancy outcomes in KT and CKD patients. 
 
Materials and methods 
Data sources  
The present study was planned in the context of the activities of the Study group on  
“Kidney and Pregnancy” of the Italian Society of Nephrology. In the absence of 
Registry data on pregnancy after renal transplantation, the present analysis was based 
on systematic phone interviews and e-mail contacts with all the Italian transplant 
Centers. The study database we built will be the basis for a prospective update. 
By June, 2014, answers had been obtained from 24/37 Kidney Transplant Centers that 
were active at December, 2013. Based on the data of the Italian Regions with fully 
updated archives, we estimated that the survey covers about 75% of the Italian kidney 
transplant population. The database includes data on pregnancies that have been 
reported since 1978; however, due to differences recorded over time in obstetrics, 
only deliveries as of January 1
st
, 2000 were included in the present analysis (43). 
Data regarding CKD patients and low-risk controls were obtained from the 2014 
update of the TOCOS database (Torino-Cagliari Observational Study), described in 
detail elsewhere (42). At December 2014, after excluding pregnancies in dialysis or 
after kidney transplantation, the TOCOS cohort consisted of 610 live-born singletons 
from CKD mothers and 1,418 low-risk live-born singleton deliveries.  
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Selection criteria  
We decided to focus on the more robust data of live-born babies since these data are 
less subject to reporting biases, which are common in retrospective analyses, 
considering also that the definitions of intrauterine death, abortion, and perinatal death 
may be difficult to interpret and may overlap, an important issue in international 
comparisons as it is also encountered in pregnancies in dialysis patients  (21, 44-45). 
Consequently, data on intrauterine deaths and abortions (pregnancy losses <24 
gestational weeks) were collected but not included in the present analysis.  
 
Collected data  
The following information was retrieved whenever appropriate in CKD and kidney 
transplant pregnancies: general data and maternal information: name (code), Center, 
date of birth, date of RRT start, data of kidney transplant, type of kidney transplant 
(cadaveric, living donor), maternal age at the start of pregnancy, type of kidney 
disease; functional data (serum creatinine, e-GFR calculated by CKD-EPI formula on 
account of its widespread use (46), blood pressure, anti-hypertensive medications) at 
the start of pregnancy and at delivery. Proteinuria (24-hour urine collection) was not 
included in the original survey in transplant patients and was available only for CKD 
subjects; a follow-up call to all transplant centers showed that these data were not 
available before or at the start of pregnancy for over 70% of patients, thus leading to 
our decision not to include proteinuria in the present analysis.  
Information on gestation and delivery: gestational week at delivery, birth weight, 
centile (according to the Italian reference Parazzini charts, the reference in the period 
of study (47)), Apgar score, weight, sex, major malformations; follow up of the 
mother (alive, in conservative treatment, on dialysis, functioning kidney graft) and of 
the child; in case of death, date and cause death. The main maternal problems in 
pregnancy were also recorded.  
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Definitions  
Causes of end-stage kidney disease were classified into broad categories: 
glomerulonephritis and systemic immunologic diseases; interstitial nephropathy and 
chronic pyelonephritis; diabetic nephropathy; polycystic kidney disease; other-
unknown.  In the CKD population 2 further categories were considered: persistent 
urinary anomalies; previous pyelonephritis with kidney scars. Furthermore, a subset 
which includes diabetic nephropathy, glomerulonephritides and systemic diseases was 
defined as “potentially progressive CKD”.  
Hypertension was defined as systolic blood pressure ≥140 and/or diastolic blood 
pressure ≥90, or anti-hypertensive therapy; patients on anti-hypertensive therapy prior 
to conception were considered hypertensive even when anti-hypertensive therapy was 
discontinued in early pregnancy.  
Pre-eclampsia (PE) was defined by employing the classic definition of hypertension 
accompanied by proteinuria ≥300 mg/24 hours after 20 weeks of gestational age in a 
previously normotensive, non proteinuric woman, in the absence of other signs or 
symptoms indicating a different nephrological diagnosis; doppler flow alterations 
were considered further support PE diagnosis. This strict diagnosis applies only to 
subjects who were normotensive and non proteinuric; since the definition of 
“superimposed PE” is not absolute, and as the overlap with CKD is higher, we did not 
include it in this study (42, 48). Due to the characteristics of CKD and kidney 
transplant patients, we did not employ the recent ACOG definitions which also 
consider an increase in serum creatinine as diagnostic (49).  
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A newborn was defined as small for gestational age (SGA) when the birth weight was 
below the 5
th
 or 10
th
 centile according to Italian birth weight references (Parazzini 
charts (47)); again, this is not an absolute definition, and while acknowledging its 
limits, we chose the 2 most frequently used cut-off points, 5
th
 and 10
th
 centile (50-53).   
Preterm delivery was defined as delivery occurring before 37 completed gestational 
weeks; early preterm delivery as delivery occurring before 34 completed gestational 
weeks and extreme early preterm delivery as delivery occurring before 28 completed 
gestational weeks (50, 54-55). 
 
Statistical analysis  
A descriptive analysis was performed as appropriate (mean and standard deviation for 
parametric data and median and range for non-parametric data). Independent t-test, 
Chi-square test, Fisher’s test, and Mann-Whitney U test were used, where indicated, 
for comparisons between patients  and controls and among groups. Significance was 
set at <0.05.  
Multiple regression analysis was performed considering the outcomes: preterm 
delivery, early preterm delivery, SGA baby, and the following covariates: age; CKD 
or kidney transplant; CKD stage at start of pregnancy; hypertension at start of 
pregnancy (SPSS vers. 18.0 for Windows, Chicago IL, USA). 
Kaplan Meier analysis was performed as time to event analysis, with observation 
going from the 24
th
 week until the date of live-born delivery. The analysis was 
performed as implemented on SAS 9.2. Differences were assessed by Log-Rank and 
Wilcoxson tests.   
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Study design: first of all, the 2 patient populations of CKD and kidney transplant 
patients were compared as per baseline data; secondly, stratification according to 
CKD stage was performed in both subsets of patients; thirdly, the “potentially 
progressive” patients were selected from the large CKD stage 1 population for 
comparison with stage 1 kidney transplant patients. Low-risk controls were used to 
contextualize the results. 
 
Ethical issues  
The observational study protocol was approved and supported by the Italian Society 
of Nephrology (Gruppo di Studio Rene e Gravidanza). The epidemiological and 
outcome study on CKD in pregnancy and the related low-risk controls was approved 
by the Ethics Committee of O.I.R.M.-Sant’Anna Hospital (protocollo di studio 
11551/c28.2;Delibera n. 335 del 4/3/2011). The observational study on kidney 
transplantation was approved by the Ethics Committee of the san Luigi Gonzaga 
hospital of the University of Torino, Italy (nota prot. n. 11655 del 26/06/13 - studio 
osservazionale pratica comitato etico n. 90/2013 Delibera n. 363 del 17/06/13).  
The clinical and research activities being reported are consistent with the Principles of 
the Declaration of Istanbul as outlined in the 'Declaration of Istanbul on Organ 
Trafficking and Transplant Tourism 
 
Results 
Baseline data  
One hundred twenty-one pregnancies in KT patients resulting in a live-born singleton 
baby were compared with 610 deliveries in CKD patients; mean age of the mothers 
was significantly higher in KT patients and, as expected by the different clinical 
histories, KT patients were more often affected by glomerulonephritides and 
immunologic diseases as compared to CKD patients in whom less severe diseases, 
mainly interstitial nephropathies, were more often present (Table 1).  
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These differences affect also the distribution of CKD stages (p<0.001). Consequently, 
serum creatinine before pregnancy or at referral is almost twice as high in KT 
patients, and the prevalence of hypertension rises from 24.4% in CKD to 55.4% in KT 
pregnancies. The overall characteristics reflect the Italian KT population during the 
study period, with a low prevalence of preemptive and living donor transplantations 
and a high prevalence of calcineurin inhibitors and of steroid treatments, that, albeit at 
low doses, are usually employed in patients with immunologic diseases who make up 
the majority of KT subjects (Table 1). 
In spite of the higher age, grafted patients were more often primigravidae, as 
compared with the CKD and low risk population (table 1, table 2). This finding may 
be explained by the long waiting time for transplantation: in fact, only a minority of 
cases was transplanted pre-emptively (5%) or received a living donor graft (14.9%).  
The main immunodepressive medications were steroids, employed in 90% of the 
cases, and calcineurin inhibitors (Cyclosporine A, in 51.7% and Tacrolimus, in 
40.8%); Azathyoprine was used in 35% of the cases, resulting in 10 different drug 
combinations (Table S1, SDC, http://links.lww.com/TP/B390). No difference 
according to the main calcineurin inhibitor was found in the logistic regression 
analysis (Table S2, SDC, http://links.lww.com/TP/B390). 
Main outcomes and outcomes across CKD stages 
Given the baseline differences, timing of delivery is not surprisingly significantly 
different between KT and CKT patients, and in both situations versus low-risk 
pregnancies (p<0.0001) (Figure 1).  
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Stratification for CKD stage, which is reported in Table 2, shows an increase of 
incidence of preterm delivery and early preterm delivery across functional stages, 
significant in CKD patients (Chi square p <0.05), but not reaching significance in the 
smaller KT cohort.  
The KT cohort is characterised by a higher incidence of caesarean sections (CS) 
across all CKD stages. The pattern suggests a widespread policy of CS in KT patients, 
regardless of stage and comorbidity, to be further addressed in dedicated analyses.  
With the exception of cesarean sections, the comparison between KT and CKD 
highlighted a substantial equivalence of the outcomes in stage 2 and in stage 3-5 
patients that were taken into consideration, as also shown in Figure 2 which depicts 
centile distribution and age at birth in male and female babies born to CKD and KT 
patients in CKD stages 3-4-5.  
However, in stage 1 patients, preterm, early and extremely preterm delivery, as well 
as small for gestational age newborns are significantly more common in KT patients 
(Table 2). Due to the impossibility to clearly diagnose preeclampsia in the CKD 
population, this outcome was not considered; none of the patients with a kidney graft 
developed HELLP syndrome in pregnancy or immediately after.  
Multivariate logistic regression analysis, shown in Table 3, was performed for 
preterm delivery, early preterm delivery and small for gestational age baby, while 
cesarean section was not analyzed, because of colinearity with KT; the analysis 
confirms the relevance of CKD stage (RR of 3.42 and 3.78 for early preterm and 
preterm delivery) and of baseline hypertension (RR of 3.68 and 3.16 for early and 
preterm delivery) but not of being a KT recipient versus being a CKD patient, even if 
differences may be offset by the small sample size.  
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Furthermore, the multivariate analysis confirms the significant effect of parity on 
early preterm delivery (but not on preterm delivery an SGA); adding parity to the 
model does not affect the equivalence between KT and CKD (table 3).  
 
Main outcomes in CKD stage 1 patients: KT, CKD and “potentially progressive” 
CKD versus the low risk control population. 
On account of the high heterogeneity of the CKD population, by including patients 
with a single kidney scar as well as patients with systemic, potentially progressive 
diseases, such as glomerulonephritis or diabetic nephropathy, a further comparison 
was carried out on patients with “potentially progressive” CKD. All patients were also 
compared to low-risk controls (Tables 4-5, Figures 3-4). 
While all subsets of stage 1 patients differ from the low-risk controls with regard to 
most or all of the outcomes we considered, the differences between KT and CKD 
pregnancies disappear if only “potentially progressive” diseases are considered (Table 
4).  Timing of delivery and the distribution of weight according to gestational week at 
delivery follow the same distribution in these 2 subsets (Figures 3-4).  
Hypertension was confirmed as a significant outcome modulator by logistic 
regression analysis, while parity or being a KT or CKD patient had no effect on the 
outcomes (Table 5). 
Discussion 
Pregnancy is a great achievement for many women with chromic kidney disease 
before or after the start of renal replacement therapy; the decision to undertake a 
pregnancy may be extremely difficult, and the communication of medical risks should 
be balanced by respect of life priorities (38, 56-57).   
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Risk assessment on which counseling is based usually considers pregnancy outcomes 
in the overall population or in low-risk pregnancies (5-6, 17, 27).  
The aim of the present study is to offer some insight into a complementary point of 
view: the patients’ risks throughout their disease evolution, from CKD to KT. Our 
data show that the risk for 2 of the main pregnancy-related outcomes are similar in 
patients with comparable degrees of renal function impairment, in the pre-ESRD 
phase or after KT, and are modulated by the presence of hypertension (Tables 2-3, 
Figures 1-2).  
While the highly heterogeneous group of stage 1 CKD patients has overall better 
outcomes than KT patients, the differences disappear when only patients with 
“potentially progressive disease” are selected from among the large subset of stage 1 
CKD patients. This is probably due to the fact that in our CKD cohort there is a high 
prevalence of interstitial diseases, with normal renal function, no hypertension and no 
proteinuria. Hence, we selected subjects with “potentially progressive disease”, more 
similar to KT patients, in whom the immunological challenges and the reduced 
nephron mass make progression over time almost the rule (Tables 4-5, Figures 3-4).  
From the physiopathologic point of view, our data suggest that once kidney function 
impairment is present, it represents a major determinant of the outcomes, thus 
offsetting the influence of therapy and of type of disease, and underlining the 
importance of the functioning nephron mass, as already reported in CKD patients (19-
20, 31, 42). Conversely, the results observed in patients with normal kidney function 
may support either the role of the nephron mass (since patients with “potentially 
progressive” CKD may be in the “gray area” in which a substantial parenchymal 
reduction is not detected by conventional renal functional tests), or the role of the 
immunologic challenge shared by glomerulonephritides, systemic diseases and KT. 
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The latter explanation is in line with the immunological hypothesis of the 
pathogenesis of preeclampsia and related hypertensive disorders of pregnancy, whose 
role in the development of adverse outcomes in CKD is only partially understood (58-
61).  
From the clinical point of view, our data may add support to the counseling of both 
non-transplanted CKD and KT patients. In fact, in the past, non-KT patients with 
advanced CKD were often discouraged from undertaking pregnancy, although in 
some cases they were told that their chances could be improved by a successful KT 
(41, 62-64). However, the conditions that were classically considered “safe” for 
pregnancy following KT identified only a subset of “best patients” (1-2 years after 
KT, good real function, no or low-grade proteinuria normotension). In both 
conditions, therefore, a gray area encompassed the patients with severe renal 
functional reduction (62-67).  
The great advances in pregnancy on dialysis have led to a paradigm shift; the 
increasingly good results with extended dialysis reduce the fear that the need to start 
or restart dialysis in pregnancy will invariably lead to adverse outcomes (40, 45, 68-
71). Consequently, we may also expect an increase in patients with advanced CKD 
before or after KT who want to have a baby, in particular when increasing maternal 
age leads the patients to consider age-related sub-fertility.  
The demonstration that the risk of adverse pregnancy outcomes for KT patients is 
similar to that of non transplanted CKD patients with a corresponding degree of 
kidney function impairment and hypertensive status, should reassure KT patients 
about the lack of detrimental effects of their immunosuppressive therapy, at least on 
“macro-events”, such as delivery of a small for gestational age, preterm baby (Tables 
3-5). Further, our study suggests that the broad creatinine-based categories that are 
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employed to distinguish high and low risk KT pregnancies should be broken down 
into more precise staging (Table 2). Our observation of similar risks in CKD and KT 
patients may support undertaking pregnancy in the pre-ESRD stage, at least in 
patients without a living donor, given the long waiting lists, the impossibility to 
foresee kidney function after KT and the consideration that increasing maternal age is 
associated not only with fertility reduction but also with an increase in adverse 
pregnancy-related outcomes (72-73).  
Although ours is a novel study, it has several limitations, partly shared by other 
studies on pregnancy in CKD or after KT (5, 16, 21, 45).  
Relatively large numbers became small after stratification, thus reducing the statistical 
power.  
The databases are heterogeneous: while data on CKD patients was gathered 
prospectively, the database on KT was the result of a retrospective inquiry, and 
reporting biases cannot be completely ruled out. Therefore, we hope that the data here 
discussed may raise attention and lead to running further large prospective studies on 
these issues.  
While no GFR formula is devoid of biases, errors may increase in pregnancy after 
KT, considering also that CNIs may cause a decrease in GFR (however measured) 
with an indirect effect on outcome (25-26, 39-30, 32, 46, 74-76). However, a 
common, simple assessment, as the CKD-EPI formula, chosen for its wide diffusion, 
is probably at present the only way to carry out clinical comparisons.  
Considering the importance of proteinuria in pregnancy-related outcomes, a major 
bias is the absence of this information in our database; this was due to lack of 
sufficient information in the original clinical charts, probably because attention to 
kidney function assessment and 24-hour proteinuria is only relatively recent in this 
setting (and patients with relevant proteinuria were probably often discouraged from 
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undertaking pregnancy). The data has been added to the prospective database for 
future studies, once more stressing the need for new, detailed, and sharable 
information to support counseling and manage pregnancies in KT and CKD patients.  
Caesarean sections were more common in KT patients, in all stages; this pattern may 
suggest a policy preferring a priori this mode of delivery in KT patients, but this 
important issue should be assessed by dedicated analyses.  
Lastly, we do not have data on assisted fertilization techniques in our CKD and KT 
populations (low-risk cases are by definitions spontaneous pregnancies). This item 
was added in the prospective database; however, since in Italy until recently the 
access to assisted fertilization techniques was limited to cases without comorbidity, 
the role of in vitro fertilization was probably negligible in the present study 
population.  
 
In summary, the present study, based upon a large multicenter cohort of pregnancies 
in KT patients whose data were compared to nontransplanted CKD and low-risk 
pregnancies, suggests that the patterns observed in KT closely correspond to those 
observed in non transplanted CKD with a comparable degree of kidney function 
impairment or with normal renal function and “potentially progressive” disease.  
These findings, reassuring on lack of a clear detrimental effect of immunosuppressive 
treatments, stress the importance of kidney function and hypertension as determinants 
of pregnancy-related outcomes and suggest the need for more detailed stratification of 
kidney function for risk assessment after KT. They also confirm that the differences 
versus the low-risk population are also observed in patients with normal renal 
function, and may support the usefulness of tailoring counseling on the various phases 
of CKD.  
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Figures: 
Figure 1: Gestational age at delivery in low-risk controls, kidney transplant patients 
and CKD patients. 
 
Figure 2: Gestational age at delivery in low-risk controls, kidney transplant patients 
and  stage 1 CKD patients with “potentially progressive” disease. 
 
Figure 3: Relationship between weight and gestational age, with respect to the 
Parazzini graphs, in KT stage 3-4-5 patients and in CKD stage 3-4-5 patients.  
 
Figure 4: Relationship between weight and gestational age, with respect to the 
Parazzini graphs, in KT stage 1 patients and in CKD stage 1 patients with “potentially 
progressive disease”. 
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Table 1. Baseline characteristics of the study population: singletons, live-born 
deliveries 
 
 
Legend: ADPKD: autosomal dominant chronic kidney disease; CKD: chronic kidney 
disease; control low-risk pregnancies: primiparous: 57.5% (ns versus CKD and 
<0.001 vs KT). * KT: data on parity available in 113 cases.  
 
  
 
Kidney 
transplant 
(KT) 
Chronic 
kidney 
disease 
(CKD) 
P 
 KT - 
CKD 
N pregnancies 121 610  
Age at pregnancy (mean and std; years) 34.1 ± 3.7 31.9 ± 5.5 <0.001 
Primiparous (*) 85 (75.2%) 341 (55.9%) <0.001 
Glomerular, diabetes and immunological 
disease n (%) 
66 (54.5%) 127 (20.8%) 
<0.001 
Interstitial diseases, including previous APN n 
(%) 
9 (7.4%) 
254 
(41.6.%) 
ADPKD n (%) 3 (2.5%) 30 (4.9%) 
Other not known  n (%) 43 (35.6%) 199 (32.6%) 
CKD stage 1 n (%) 26 (21.5%) 481 (78.9%) 
<0.001 
CKD stage 2 n (%) 52 (43.0%) 87 (14.3%) 
CKD stage 3 n (%) 42 (34.7%) 32 (5.2%) 
CKD stage 4-5 n (%) 1 (0.8%) 10 (1.6%) 
Serum creatinine (before or referral) (median, 
min-max; mg/dL) 
1.07 (0.6-
2.4) 
0.61 (0.3-
7.9) 
<0.001 
Hypertension (before or referral) n (%) 67 (55.4%) 148 (24.4%) <0.001 
Months of dialysis pretransplantation (median, 
min-max) 
27.5 (0-194) - 
 
Months between transplantation and pregnancy 
(median, min-max) 
62 (14-278) - 
 
Preemptive transplantation n (%) 6 (5%) -  
Living donor transplantation  n (%) 18 (14.9%) -  
Cyclosporine A therapy n (%) 62 (51.7%) -  
Tacrolimus therapy n (%) 49 (40.8%) -  
No calineurin inhibitors 
9/120 
(7.5%) 
- 
 
Treatment with steroids 108 (90%) -  AC
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Table 2. Main materno-foetal outcomes across CKD-EPI stages in kidney 
transplant and in patients with CKD (pre- ESRD) 
 
 CKD-EPI stage 1 (n) CKD-EPI stage 2 (n) 
CKD-EPI stages 3-5 
(n) 
 KT CKD p KT CKD p KT CKD P 
N pregnancies 26 481  52 87  43 42  
Primiparous  
n (%) 
17 
(68.0%) 
264 
(54.9%) 
0.280 
39 
(78.0%) 
50 
(57.5%) 
0.025 
29 
(76.3%) 
27 
(64.3%) 
0.353 
Age at 
pregnancy 
(yrs) 
33.4±4.4 
31.4 ± 
5.7 
0.077 33.6 ± 3.6 
33.7 ± 
4.6 
0.861 
34.9 ± 
3.3 
33.0 ± 
4.5 
0.030 
Cesarean 
sections (%) 
19  
(73.1%) 
212  
(44.2%) 
0.007 
39  
(76.5%) 
59 
(67.8%) 
0.375 
37  
(86%) 
29  
(69%) 
0.100 
Gestational 
week 
36 ± 3.1 37.6±2.4 0.001 35.24±3.2 
35.8 ± 
3.1 
0.290 35 ± 2.5 
34.0 ± 
3.2 
0.140 
Preterm  
(<37 w) 
12  
(46.2%) 
106  
(22.1%) 
0.010 
31 
(60.8%) 
44 
(50.6%) 
0.325 
28  
(68.3%) 
33 
(78.6%) 
0.420 
Early preterm  
(<34 w) 
4  
(15.4%) 
30  
(6.2%) 
0.088 
14 
(27.5%) 
17 
(19.5%) 
0.388 
14 
(34.1%) 
15 
(35.7%) 
0.999 
Extreme 
preterm (<28 
w) 
1  
(3.8%) 
2  
(0.4%) 
0.147 
1  
(2%) 
3  
(3.4%) 
0.999 0 
1  
(2.4%) 
0.999 
Weight at birth 
(g) 
2573 ± 
810 
2960 ± 
623 
0.003 
2454 ± 
610 
2509 ± 
692 
0.640 
2229 ± 
672 
2089 ± 
747 
0.370 
SGA <10% 
(Parazzini) 
6/25 
(24.0%) 
63 
(13.2%) 
0.134 
8/50  
(16%) 
13 
(15.5%) 
0.999 
10/40 
(25%) 
12 
(29.3%) 
0.850 
SGA <5% 
(Parazzini) 
4/25 
(16.0%) 
23  
(4.8%) 
0.038 
4/50 
(8.2%) 
4  
(4.8%) 
0.471 
3/40 
(7.5%) 
4  
(9.8%) 
0.999 
SGA <10% 
(Ines) 
4/25 
(16.0%) 
53 
(11.1%) 
0.511 
4/49 
(8.2%) 
9  
(10.3%) 
0.770 
8/40 
(20%) 
8  
(19%) 
0.999 
SGA <5% 
(Ines) 
3/25 
(12.0%) 
17  
(3.5%) 
0.070 
2/49 
(4.1%) 
3  
(3.4%) 
0.999 
4/40 
(10%) 
2  
(4.8%) 
0.430 
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CKD stage 
shift 
6/19 
 (31.6%) 
32/481 
(6.7%) 
0.002 
9/38 
(23.7%) 
 10/87 
(11.5%) 
0.14 
 1/32 
(3.1%) 
6/42 
 
(14.3%) 
0.13 
 
Legend: CKD: chronic kidney disease; KT: kidney transplantation; ESRD: end stage 
renal disease; SGA: small for gestational age. 
P: between CKD and KT patients in each stage.  
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Table 3. Multivariate logistic regression analysis: transplantation versus CKD 
(all cases, all stages) 
 
 
Preterm delivery 
<34 weeks 
(N= 92/717) 
Preterm delivery 
<37 weeks 
(N= 248/717) 
SGA (Parazzini) 
<10
th
 centile 
(N= 110/709) 
Age < 33 years 1 1 1 
Age >=33 
years OR (IC) 
1.38 (0.84-2.29) 1.21 (0.85-1.73) 0.68 (0.45-1.05) 
CKD Stage 1 1 1 1 
CKD stages 
2+3+4   
OR (IC) 
3.25 (1.92–5.49) 3.81 (2.57-5.65) 1.48 (0.90-2.43) 
Normotension 1 1 1 
Hypertension 
OR (IC) 
3.86 (2.35-6.32) 3.18 (2.20-4.59) 1.13 (0.71-1.80) 
CKD 1 1 1 
KT 
OR (IC) 
1.04 (0.58-1.88) 1.16 (0.71-1.92) 1.23 (0.67-2.25) 
Primiparous  1 1 1 
Multiparous 
OR (IC) 
0.43 (0.25-0.74) 0.83 (0.58-1.19) 0.86 (0.56-1.32) 
 
Legend: CKD: chronic kidney disease; KT: kidney transplantation; SGA: small for 
gestational age. 
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Table 4. Main Materno-foetal outcomes in CKD-EPI stage 1 transplanted 
patients, CKD patients, CKD patients with “progressive disease” and low-risk 
controls  
 
 
KT  
stage 1 
CKD  
stage 1 
CKD  
stage 1 with 
“potentially 
progressive” 
disease 
Low-risk 
controls 
P 
(KT vs 
CKD) 
 
P 
(KT vs 
progressive 
CKD) 
 
P 
(KT vs 
controls)  
 
 
P 
(CKD 
vs 
controls) 
 
N 
pregnancies 
26 481 63 1418     
Primiparous 
n (%) 
17 
(68.0%)  
264 
(54.9%)  
43 (68.3%)  
815 
(57.5%) 
0.280 1.000 0.394 0.348 
Age at 
pregnancy 
(yrs) 
33.4 ± 
4.4 
31.4 ± 5.7 30.9 ± 5.9 31.2 ± 5.5 0.077 0.323 0.470 0.559 
Cesarean 
sections 
(%) 
19  
(73.1%) 
212  
(44.2%) 
39  
(61.9%) 
379  
(26.7%) 
0.007 0.446 <0.001 <0.001 
Gestational  
week 
36.0 ± 
3.1 
37.6 ± 2.4 36.8 ± 2.7 39.0 ± 1.6 0.001 0.362 <0.001 <0.001 
Preterm 
(<37 w) 
12  
(46.2%) 
106  
(22.1%) 
25  
(39.7%) 
89  
(6.3%) 
0.010 0.744 <0.001 <0.001 
Early 
preterm 
 (<34 w)  
4  
(15.4%) 
30  
(6.2%) 
6  
(9.5%) 
13  
(0.9%) 
0.088 0.470 <0.001 <0.001 
Extreme 
preterm 
(<28 w)  
1  
(3.8%) 
2  
(0.4%) 
0 
2  
(0.1%) 
0.147 - 0.053 0.267 
Weight at 
birth 
 (g) 
2573 ± 
810 
2960 ± 
623 
2879 ± 627 
3232 ± 
476 
0.003 0.070 <0.001 <0.001 
SGA <10% 6/25  63  7  157  0.134 0.181 0.055 0.262 
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Legend: CKD: chronic kidney disease; KT: kidney transplantation; ESRD: end stage 
renal disease; SGA: small for gestational age. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Parazzini) (24.0%) (13.2%) (11.1%) (11.1%) 
SGA <5% 
(Parazzini) 
4/25  
(16.0%) 
23  
(4.8%) 
2  
(3.2%) 
63  
(4.5%) 
0.038 0.052 0.026 0.854 
SGA <10%  
(Ines) 
4/25  
(16.0%) 
53  
(11.1%) 
7  
(11.1%) 
120  
(8.5%) 
0.511 0.500 0.266 0.110 
SGA <5% 
 (Ines) 
3/25  
(12.0%) 
17  
(3.5%) 
0 
45  
(3.2%) 
0.070 - 0.048 0.811 
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Table 5. Logistic regression analysis: transplantation versus CKD with 
“progressive disease” (stage 1 according to CKD-EPI) 
 
 
Preterm delivery 
<34 weeks 
Preterm delivery 
<37 weeks 
SGA 
Parazzini<10
th
 
centile 
Age < 33 years 1 1 1 
Age >=33 
years OR (IC) 
0.18 ( 0.03 – 1.01) 0.94 (0.37 – 2.38) 0.54 (0.15 – 1.99) 
Normotension 1 1 1 
Hypertension 
OR (IC) 
2.99 (0.69- 12.96) 3.07 (1.18 – 8.02) 1.78 (0.48- 6.51) 
CKD 1 1 1 
KT 
OR (IC) 
1.70 (0.37 - 7.72) 0.80 (0.29– 2.27) 2.46 (0.64 – 9.48) 
Primiparous  1 1 1 
Multiparous 
OR (IC) 
1.13 (0.24-5.26) 1.01 (0..38-2.72) 0.67 (0.16-2.86) 
 
Legend: CKD: chronic kidney disease; KT: kidney transplantation; SGA: small for 
gestational age. 
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Table S1: Immunosuppressive medications. The different combinations in 
kidney transplant recipients 
 
 
 
All  KT (120) 
N (%) 
Stage 1 (25) 
N (%) 
Stage 2 (52) 
N (%) 
Stages 3-5 (42) 
N (%) 
Drug frequency 
Steroid  108 (90.0) 24 (96.0) 42 (80.8) 42 (97.7) 
CyA 62 (51.7) 4 (16.09 30 (57.7) 28 (65.1) 
Tacrolimus 49 (40.8) 18 (72.0) 18 (34.6) 13 (30.2) 
AZA 42 (35.0) 7 (28.0) 21 (40.4) 14 (32.6) 
Drug combination frequency 
Steroid alone 2 (1.7) 1 (4.0) 1 (1.9) - 
CyA alone 1 (0.8) - 1 (1.9) - 
Tacrolimus alone 1 (0.8) - 1 (1.9) - 
Steroid + CyA 42 (35.0) 3 (12.0) 19 (36.5) 20 (46.5) 
Steroid + CyA + AZA 14 (11.7) 1 (4.0) 6 (11.5) 7 (16.3) 
Cya + Aza 5 (4.2) - 4 (7.7) 1 (2.3) 
Steroid + Tacrolimus 32 (26.7) 14 (53.8) 9 (17.3) 9 (20.9) 
Steroid + Tacrolimus +AZA 11 (9.2) 3 (12.0) 4 (7.7) 4 (9.3) 
Tacrolimus + AZA 5 (4.2) 1 (4.0) 4 (7.7)  
Steroid + AZA 7 (5.8) 2 (8.0) 3 (5.8) 2 (4.7) 
Note: information is missing in 1 case 
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Table S2. Logistic regression analysis: transplantation  
 
 
Preterm delivery 
<34 weeks 
  
Preterm delivery 
<37 weeks 
  
SGA Parazzini<10
th
 
centile 
  
Age < 34 years 1 1 1 
Age >=34 years 
OR (IC) 
2.27 ( 0.89 – 5.79) 1.61 ( 0.72 – 3.61) 0.40 ( 0.14 – 1.11) 
Normotension 1 1 1 
Hypertension 
OR (IC) 
1.07 (0.45- 2.54) 1.52 (0.69- 3.37) 1.25 (0.45- 3.49) 
Stage 1 1 1 1 
Stages 2+3+4   
OR (IC) 
2.94 (0.73 – 11.79) 2.16 (0.76 – 6.16) 1.60 (0.37 – 6.87) 
Cyclosporine 1 1 1 
Tacrolimus 
OR (IC) 
1.07 (0.42-2.71) 1.001 (0.42-2.39) 1.02 (0.34-3.06) 
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